Immunization articles from across Nature Portfolio

Treatment of patients with advanced hepatocellular carcinoma with a personalized DNA vaccine in combination with anti-PD-1 therapy was safe and led to encouraging clinical efficacy, with immunological analyses confirming the induction of tumor antigen-specific T cell responses.

Immunotherapy using dendritic cell (DC)-based vaccination has been exploited in the clinic for cancer treatment. Here the authors report the results of a randomized, placebo-controlled, phase 3 trial of adjuvant blood-derived DC cell-based therapy in patients with stage IIIB and IIIC melanoma.

CD3 bispecific antibodies (bsAbs) have demonstrated promising clinical responses in hematological malignancies but clinical benefit in solid tumors has been limited. Here the authors report that pre-treatment vaccination promotes the infiltration of tumor-(un)related effector CD8 T cells, improving the efficacy of CD3 bsAbs in solid tumors.

CAR T cells engineered to express IL-10 eradicate solid tumors and metastases.

Results from two parallel trials suggest that withholding methotrexate only after the second dose of a COVID vaccine is safe and effective in patients with rheumatoid arthritis or psoriatic arthritis.

Established models of behavioural science can help to explain the suboptimal COVID-19 vaccine uptake even in countries with a plentiful supply, showing that increasing vaccination is not just about increasing knowledge and motivation, but also about increasing the opportunity for vaccination.

In patients with autoimmune rheumatic disease, methotrexate therapy has been associated with poor immune response to vaccines, including those intended to provide protection against COVID-19. Emerging evidence supports the practice of temporarily discontinuing this treatment in order to improve immunogenicity.

The non-pharmaceutical interventions that were introduced to limit the spread of SARS-CoV-2 have also affected the transmission of respiratory syncytial virus, particularly its seasonality, with implications for the deployment of new monoclonal antibodies and vaccines.

PIK3CA gain-of-function mutations are among the most common alterations in human solid cancers. Through the use of stimulation-induced functional T cell receptor (TCR) sequencing (SIFT-seq), a panel of TCRs that bind a mutant PI3Kα shared neoantigen was identified, including a potential clinical candidate that engages cancer cells via a distinctive CDR3β loop.